Fichtner I - Search Results

1

Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.

Piggott L, Silva A, Robinson T, Santiago-Gómez A, Simões BM, Becker M, Fichtner I, Andera L, Young P, Morris C, Barrett-Lee P, Alchami F, Piva M, Vivanco MD, Clarke RB, Gee J, Clarkson R. Piggott L, et al. Among authors: fichtner i. Clin Cancer Res. 2018 May 15;24(10):2452-2463. doi: 10.1158/1078-0432.CCR-17-1381. Epub 2018 Jan 23. Clin Cancer Res. 2018. PMID: 29363524

2

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J. Fichtner I, et al. Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138. Clin Cancer Res. 2008. PMID: 18927285 Free article.

3

Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.

Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, Fichtner I. Hoffmann J, et al. Among authors: fichtner i. Clin Cancer Res. 1999 Aug;5(8):2198-204. Clin Cancer Res. 1999. PMID: 10473106

4

Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations.

Naundorf H, Jost-Reuhl B, Becker M, Reuhl T, Neumann C, Fichtner I. Naundorf H, et al. Among authors: fichtner i. Breast Cancer Res Treat. 2000 Mar;60(1):81-92. doi: 10.1023/a:1006334131241. Breast Cancer Res Treat. 2000. PMID: 10845812

5

Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.

Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, Klar U, Hoffmann J. Hammer S, et al. Among authors: fichtner i. Clin Cancer Res. 2010 Mar 1;16(5):1452-65. doi: 10.1158/1078-0432.CCR-09-2455. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179216

6

Development and characterization of a tamoxifen-resistant breast carcinoma xenograft.

Naundorf H, Becker M, Lykkesfeldt AE, Elbe B, Neumann C, Büttner B, Fichtner I. Naundorf H, et al. Among authors: fichtner i. Br J Cancer. 2000 Jun;82(11):1844-50. doi: 10.1054/bjoc.2000.1156. Br J Cancer. 2000. PMID: 10839300 Free PMC article.

7

In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.

Fichtner I, Becker M, Zeisig R, Sommer A. Fichtner I, et al. Eur J Cancer. 2004 Apr;40(6):845-51. doi: 10.1016/j.ejca.2003.11.030. Eur J Cancer. 2004. PMID: 15120040 Review.

8

Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM.

Becker M, Sommer A, Krätzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Becker M, et al. Among authors: fichtner i. Mol Cancer Ther. 2005 Jan;4(1):151-68. Mol Cancer Ther. 2005. PMID: 15657362

9

Expression of CD44 isoforms in human breast carcinoma xenografts is not influenced by the treatment of mice with cytostatics or (anti-)hormones.

Dehmel A, Becker M, Lemm M, Fichtner I. Dehmel A, et al. Among authors: fichtner i. Anticancer Res. 1999 May-Jun;19(3A):1977-87. Anticancer Res. 1999. PMID: 10470143

10

Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.

Rolff J, Becker M, Merk J, Hoffmann J, Fichtner I. Rolff J, et al. Among authors: fichtner i. Target Oncol. 2016 Aug;11(4):507-14. doi: 10.1007/s11523-015-0415-4. Target Oncol. 2016. PMID: 26817645

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Search Page

Filters